Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV002491496 | SCV002777269 | uncertain significance | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2021-08-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002491496 | SCV004568968 | likely benign | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2025-01-29 | criteria provided, single submitter | clinical testing | |
Clinical Genetics, |
RCV001699517 | SCV001925801 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Diagnostic Laboratory, |
RCV001699517 | SCV001963131 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV004738179 | SCV005352668 | uncertain significance | APOB-related disorder | 2024-04-12 | no assertion criteria provided | clinical testing | The APOB c.11503A>C variant is predicted to result in the amino acid substitution p.Ile3835Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0062% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |